Enclomisign 50 mg: Enclomiphene Uses, Testosterone Support, Fertility, and Side Effects
Written by Dr. Zack Ferris in TheSkyMeds Editorial Standards
Medically reviewed by Jonathan Reed, Medical Content Reviewer Aug 31 2026
Enclomisign 50 mg is marketed as a tablet containing enclomiphene, a selective estrogen receptor modulator (SERM) being promoted for low testosterone and male fertility. Enclomiphene can stimulate the body's own hormonal pathway, increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which can raise testosterone while generally preserving sperm production in clinical studies. However, this promising hormonal effect needs important context: enclomiphene is not an FDA-approved medicine, the European Medicines Agency previously refused marketing authorization, and Indian authorities recently warned that enclomiphene products were being manufactured or marketed without required central approval. In addition, the 50 mg strength marketed as Enclomisign is higher than the 6.25 mg, 12.5 mg, and 25 mg doses evaluated in several key male hypogonadism trials. This does not mean every person with low testosterone should receive enclomiphene—or that a higher tablet strength provides greater benefit. This guide explains what enclomiphene does, what research shows about testosterone and fertility, the limitations of Enclomisign 50 mg, and the side effects and safety questions men should understand before considering treatment.
What Is Enclomisign 50 mg and How Does Enclomiphene Work?
Enclomisign 50 mg is currently marketed in India as containing 50 mg of enclomiphene. Current pharmacy and trade listings identify the product with that composition, although commercial listings are not equivalent to regulatory approval or independent verification of therapeutic claims.
Enclomiphene itself is the trans-isomer of clomiphene. Rather than supplying testosterone from outside the body, it acts on estrogen feedback within the hypothalamic-pituitary-gonadal axis—the hormone communication system connecting the brain and testes.
How does enclomiphene raise testosterone?
Enclomiphene blocks some estrogen signaling at the hypothalamus and pituitary. This can increase release of LH and FSH.
LH tells the Leydig cells in the testes to make testosterone. FSH plays an important role in sperm production.
This mechanism differs fundamentally from testosterone replacement therapy (TRT), which supplies testosterone directly and can suppress LH, FSH, and sperm production through negative hormonal feedback.
The randomized clinical evidence on enclomiphene and sperm preservation found that men receiving enclomiphene experienced increased testosterone, LH, and FSH while sperm concentrations were maintained, whereas topical testosterone suppressed gonadotropins and reduced spermatogenesis.
Is enclomiphene the same as clomiphene?
No. They are closely related but not identical.
Clomiphene citrate contains two isomers: enclomiphene and zuclomiphene. Enclomiphene is the trans-isomer thought to provide much of clomiphene's estrogen-antagonist effect that stimulates LH and FSH.
Clomiphene has been used off-label in men for many years, while enclomiphene was developed as an isolated compound for potential treatment of secondary hypogonadism.
Can Enclomiphene Support Testosterone in Men?
Clinical trials show that enclomiphene can increase testosterone in selected men with secondary hypogonadism, particularly when LH is low or inappropriately normal. That does not establish it as a general testosterone booster for healthy men or men with unexplained fatigue, reduced libido, or normal testosterone levels.
Secondary hypogonadism means the testes may still be capable of producing testosterone, but stimulation from the hypothalamus or pituitary is inadequate.
What have clinical trials found?
A randomized phase II study in men with secondary hypogonadism found that enclomiphene increased morning testosterone as well as LH and FSH. Testosterone increases were comparable with topical testosterone treatment, but sperm counts were preserved with enclomiphene.
Two later randomized phase III studies involving overweight men with secondary hypogonadism also found increased testosterone, LH, and FSH after enclomiphene treatment. Sperm concentrations remained within the normal range, while testosterone gel caused a marked reduction in spermatogenesis.
A 2025 systematic review and meta-analysis of randomized trials likewise examined clomiphene and enclomiphene as SERMs for functional male hypogonadism, reflecting continued scientific interest in this treatment approach.
Does higher testosterone mean symptoms definitely improve?
No. This is one of the most important limitations of the evidence.
The European Medicines Agency reviewed four main enclomiphene studies involving 588 patients. Although testosterone increased, regulators concluded that the studies had not adequately demonstrated improvements in clinically meaningful outcomes such as libido, erectile dysfunction, body composition, or other symptoms of hypogonadism.
The EMA therefore concluded that clinical benefit had not been sufficiently established and refused marketing authorization for EnCyzix, an enclomiphene product, in 2018.
The EMA assessment of enclomiphene for male hypogonadism is particularly useful because it distinguishes improvement in a laboratory testosterone number from proof that patients actually feel or function better.
Enclomiphene has evidence that it can raise testosterone in selected men with secondary hypogonadism while preserving sperm production. That is not the same as proving that every man with “low T” will experience better energy, libido, erections, muscle mass, or fertility—and it does not establish Enclomisign 50 mg as an approved treatment regimen.
Enclomiphene and Fertility: How Is It Different From Testosterone Therapy?
Fertility preservation is one of the main reasons enclomiphene has attracted clinical interest. Unlike external testosterone, enclomiphene stimulates the body's own LH and FSH rather than suppressing them.
This distinction can matter greatly for men who are trying to conceive.
Why can testosterone therapy reduce sperm production?
External testosterone raises circulating testosterone but tells the hypothalamus and pituitary that additional stimulation is unnecessary.
LH and FSH consequently fall. Inside the testes, the very high local testosterone concentrations required for normal sperm production can decline, causing sperm counts to fall substantially or sometimes reach zero.
The AUA/ASRM male infertility guideline therefore states that testosterone monotherapy should not be prescribed to men interested in current or future fertility.
Does enclomiphene improve male fertility?
Evidence is stronger for preserving sperm concentration while increasing testosterone than for proving that enclomiphene increases pregnancy or live-birth rates.
Trials found maintained sperm concentrations with enclomiphene compared with suppression during topical testosterone treatment.
That does not mean enclomiphene is an established fertility treatment for every cause of male infertility. Low sperm count can arise from genetic disorders, varicocele, obstruction, primary testicular failure, infections, medications, hormonal abnormalities, or other causes that require different management.
The AUA and ASRM male infertility guideline states that clinicians may consider SERMs, aromatase inhibitors, hCG, or combinations in infertile men with low testosterone, but rates the evidence as Grade C and notes that most such medicines are not FDA-approved for male use.
Enclomiphene versus external testosterone when fertility matters
Feature | Enclomiphene | Testosterone therapy |
Main hormonal approach | Stimulates endogenous testosterone production | Supplies testosterone from outside the body |
LH | Usually increases in studied secondary hypogonadism | Usually decreases |
FSH | Usually increases | Usually decreases |
Serum testosterone | Can increase | Increases with effective treatment |
Sperm production | Preserved in several enclomiphene trials | Can fall substantially |
Evidence for pregnancy/live birth | Limited | Not a fertility treatment |
Appropriate for every low-T patient? | No | No |
Regulatory status | No FDA-approved enclomiphene drug product | Multiple FDA-approved testosterone products exist |
What Does the 50 mg Strength of Enclomisign Mean?
The “50 mg” on Enclomisign describes the marketed amount of enclomiphene in the tablet. It should not be interpreted as an established standard male hypogonadism dose.
This distinction is especially important because key clinical development programs investigated lower enclomiphene doses.
What doses were studied in enclomiphene trials?
A phase II pharmacology study evaluated 6.25 mg, 12.5 mg, and 25 mg doses of enclomiphene in men with secondary hypogonadism.
FDA documentation concerning the proposed Androxal product states that the submitted product contained 12.5 mg and 25 mg enclomiphene citrate capsules. The FDA also states that there are no FDA-approved drug products containing enclomiphene citrate as the active ingredient.
Therefore, a commercially marketed 50 mg tablet should not be treated as though it were an FDA-established or trial-validated standard dose for male hypogonadism.
Is 50 mg twice as effective as 25 mg?
There is no sound basis for making that assumption.
Drug effects do not necessarily increase proportionally with milligram strength, and increasing exposure can increase adverse effects without producing additional clinical benefit.
Someone considering enclomiphene should not split, double, alternate, or otherwise design a regimen from a 50 mg tablet based on online dosing discussions. There is no universally approved enclomiphene dosage regimen to use as a self-treatment template.
Enclomiphene strengths in research versus Enclomisign 50 mg
Product/evidence context | Enclomiphene amount | What it means |
Phase II research | 6.25 mg | Investigational trial dose |
Phase II/III research | 12.5 mg | Investigational trial dose |
Phase II/III research | 25 mg | Investigational trial dose |
Proposed Androxal NDA | 12.5 mg and 25 mg | Proposed doses; product was not FDA approved |
Enclomisign marketed tablet | 50 mg | Marketed product strength, not an established FDA-approved male dose |
Appropriate personal dose | Cannot be determined from this table | Requires diagnosis and clinician assessment |
Is Enclomisign 50 mg Approved, and What Side Effects Matter?
Regulatory status is particularly important with Enclomisign because enclomiphene remains an unapproved medicine in several major jurisdictions.
FDA documentation states that there are no FDA-approved drug products containing enclomiphene citrate. The EMA refused authorization for an enclomiphene product after concluding that clinically meaningful benefit had not been adequately demonstrated and identifying safety concerns including venous thromboembolism.
In India, the regulatory issue is especially current. In August 2026, the Drugs Controller General of India reportedly instructed state regulators to act against enclomiphene products being manufactured or marketed without required Central Licensing Authority permission.
What side effects have been associated with enclomiphene?
The safety database for enclomiphene is much smaller than for long-established approved medicines, especially for prolonged treatment.
Reported or potential concerns across research and regulatory reviews include:
headache;
nausea or gastrointestinal symptoms;
changes in mood;
hot flushes;
increases in estradiol;
visual symptoms;
changes in hormone-related laboratory values; and
potential thromboembolic events, meaning blood clots in veins.
The EMA specifically highlighted venous thromboembolism as a concern when reviewing enclomiphene. It also noted limited long-term exposure data, making long-term safety difficult to define confidently.
Who should be particularly cautious?
Enclomiphene should not be treated as a casual testosterone-enhancement supplement.
Anyone with previous blood clots, unusual visual symptoms, significant liver disease, hormone-sensitive medical conditions, unexplained infertility, or other endocrine disorders needs appropriate medical assessment before hormonal treatment is considered.
Men using other hormone treatments or performance-enhancing drugs also require careful review because abnormal testosterone does not reveal its cause by itself.
How Should Low Testosterone Be Evaluated Before Considering Enclomiphene?
A single low testosterone result is not enough to establish male hypogonadism.
The Endocrine Society recommends diagnosing hypogonadism only when a man has compatible symptoms and consistently low testosterone concentrations measured with appropriate testing. It recommends repeating a morning fasting total testosterone measurement and investigating the underlying cause.
In a July 2026 statement, the Society again emphasized that low energy, reduced libido, and mood changes are nonspecific and can have causes such as obesity, medication effects, sleep disorders, or other health conditions.
Why do LH and FSH matter? (H3)
LH and FSH help distinguish between major forms of hypogonadism.
Low testosterone accompanied by low or inappropriately normal LH can suggest secondary hypogonadism, the setting in which enclomiphene has principally been studied.
Low testosterone with elevated LH may suggest primary testicular failure. In that situation, stimulating the pituitary further may produce a more limited response because the problem lies primarily within the testes. The AUA/ASRM guideline specifically notes this limitation for SERM therapy.
What else may need checking?
Depending on symptoms and history, clinical assessment may include repeat morning testosterone, LH, FSH, prolactin, estradiol in selected circumstances, semen analysis when fertility is important, and evaluation for reversible causes.
The cause matters more than simply pushing a testosterone number higher.
Obesity, sleep apnea, severe illness, opioid or glucocorticoid use, pituitary disease, and other medical conditions can influence testosterone and may require treatment of the underlying problem.
Safety: When Should You Seek Medical Advice?
Do not self-start Enclomisign 50 mg solely because a testosterone result is below a laboratory reference range or because you have fatigue, low libido, erectile problems, reduced muscle mass, or difficulty conceiving. Those symptoms have many potential explanations, and enclomiphene has not been approved as a general treatment for them.
Seek medical advice promptly if hormonal treatment is followed by visual disturbance, severe headache, chest pain, shortness of breath, one-sided leg swelling or pain, neurological symptoms, or another significant reaction. Symptoms that could indicate a blood clot require urgent evaluation.
Men trying to conceive should ideally have a fertility-focused evaluation before starting either enclomiphene or testosterone. Semen analysis, hormonal testing, examination, and the couple's reproductive circumstances can substantially change the appropriate approach.
Because Enclomisign is marketed at 50 mg while important male enclomiphene trials evaluated lower doses, do not construct a personal dosing regimen by copying online protocols or converting trial doses yourself. Product legitimacy and current local regulatory status should also be verified before use.
Conclusion
Enclomisign 50 mg is marketed as enclomiphene, a SERM that can stimulate LH and FSH and increase the body's own testosterone production. Clinical trials in selected men with secondary hypogonadism found increased testosterone while sperm concentrations were preserved, making enclomiphene scientifically interesting when fertility matters. However, increased testosterone has not translated into sufficiently proven clinical benefits for enclomiphene to gain major regulatory approval, and 50 mg is above doses studied in several pivotal trials.
If low testosterone or fertility is a concern, start with proper hormonal and reproductive evaluation rather than self-treatment. A qualified endocrinologist, urologist, or fertility specialist can determine the cause and discuss regulated, evidence-based options appropriate to your goals.
Frequently Asked Questions
1. What is Enclomisign 50 mg used for?
Enclomisign 50 mg is marketed as containing enclomiphene for testosterone and fertility-related uses. Enclomiphene has been studied mainly in men with secondary hypogonadism, where it can increase testosterone, LH, and FSH. Enclomisign itself should not be assumed to have an approved therapeutic indication.
2. Does enclomiphene increase testosterone naturally?
Enclomiphene stimulates the body's own testosterone-production pathway rather than supplying testosterone directly. Trials found increases in LH, FSH, and serum testosterone in selected men with secondary hypogonadism. This does not mean it is appropriate for men with normal testosterone or every form of hypogonadism.
3. Is enclomiphene better than TRT for fertility?
Enclomiphene has an important fertility advantage in trials because sperm concentrations were maintained while testosterone increased. External testosterone can suppress LH, FSH, and sperm production. However, enclomiphene has not been proven to improve pregnancy or live-birth rates for every cause of infertility.
4. Is Enclomisign 50 mg an approved enclomiphene dose?
No FDA-approved enclomiphene dose exists because no FDA-approved enclomiphene drug product exists. Important clinical studies evaluated doses including 6.25 mg, 12.5 mg, and 25 mg. A marketed 50 mg tablet should therefore not be interpreted as an established standard male regimen.
5. What are the side effects of enclomiphene?
Potential effects reported or considered during development include headache, gastrointestinal symptoms, hot flushes, hormonal changes, mood or visual symptoms, and possible blood-clot risk. Long-term safety remains less certain because prolonged exposure data are limited. Significant or unusual symptoms warrant medical assessment.
6. Is enclomiphene FDA approved in 2026?
No FDA-approved drug product containing enclomiphene citrate has been established as of 2026. FDA documentation specifically states that no FDA-approved enclomiphene product exists. The EMA also refused an enclomiphene marketing application because clinical benefit was insufficiently established and safety concerns remained.
Comments